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Abstract 
Background and Purpose 
-opioid receptor antagonists have potential for treating neuropsychiatric disorders. 
We have investigated the in vivo pharmacology of a novel buprenorphine analogue, 
BU10119, for the first time.  
Experimental Approach 
To determine the opioid pharmacology of BU10119 (0.3-3 mg/kg, i.p.) in vivo, the 
warm-water tail withdrawal assay was used in adult male CD1 mice. A range of 
behavioural paradigms was used to investigate the locomotor effects, rewarding 
properties and antidepressant or anxiolytic potential of BU10119. Additional groups 
of mice were exposed to a single (1 x 2h) or repeated restraint stress (3 x daily 2h) to 
determine the ability of BU10119 to block stress-induced analgesia.  
Key Results 
BU10119 alone was without any antinociceptive activity. BU10119 (1mg/kg) was 
able to block U50,488, buprenorphine and morphine induced antinociception. The 
antagonist effects of BU10119 in the tail-withdrawal assay reversed between 24-
48h. BU10119 was without significant locomotor or rewarding effects. BU10119 
(1mg/kg) significantly reduced the latency to feed in the novelty-induced hypophagia 
task and reduced immobility time in the forced swim test, compared to saline treated 
animals. There were no significant effects of BU10119 in either the elevated plus 
maze or the light dark box. Both acute and repeated restraint stress-induced 
analgesia was blocked by pretreatment with BU10119 (1mg/kg). Parallel stress-
induced increases in plasma corticosterone were not affected.    
Conclusions and Implications 
BU10119 is a mixed opioid receptor antagonist with relatively short-duration 
antagonist activity. Based on these preclinical data, BU10119 has therapeutic 
potential in the treatment of depression and other stress-induced conditions.   
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Introduction 
There is growing interest in the possibility of targeting kappa opioid receptors (-
receptors Borsodi et al. 2017) for the treatment of depression (Carroll and Carlezon, 
2013, Lalanne et al., 2014). The endogenous opioid neuropeptide dynorphin is 
released in response to stress and activates -receptors to produce pro-depressive 
behaviours (Shirayama et al., 2004, Schwarzer, 2009). In humans, activation of -
receptors has been shown to be dysphoric (Pfeiffer et al., 1986). On the other hand, 
blockade of -receptors or -receptor gene deletion have shown anti-depressant like 
effects in mice (McLaughlin et al., 2006b, McLaughlin et al., 2003).  
 
A number of high affinity, selective -antagonists exist (Carroll and Carlezon, 2013) 
which have an unusual pharmacokinetic profile that perhaps limits their translatability 
to the clinic. For example, following a single injection, the effects of the selective 
receptor antagonist norbinaltorphimine (norBNI) last for several weeks (Endoh et 
al., 1992). A number of strategies have arisen to develop alternative means of 
targeting the -receptor by producing short-acting antagonists (Aldrich et al., 2009, 
Rorick-Kehn et al., 2014, Casal-Dominguez et al., 2014, Peters et al., 2011, 
Verhoest et al., 2011, Ross et al., 2012).  
 
We have recently shown that the combination of buprenorphine (a partial opioid 
receptor agonist/ -antagonist) with naltrexone (a non-selective  antagonist) 
produces a functional short-acting -antagonist in vivo that has antidepressant-like 
activity in mice (Almatroudi et al., 2015). A similar approach of  a combination of 
buprenorphine with a antagonist samidorphan has been shown to have 
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antidepressant effects in treatment resistant depressed patients (Ehrich et al., 2015). 
While buprenorphine and naltrexone are both licensed for other indications, so may 
be attractive to translate to the clinic, the approach of using combination treatments 
may have limitations. Where buprenorphine/naltrexone combination has been trialled 
clinically for the treatment of opioid dependence (Gerra et al. 2006, Rothman et al. 
2000), naltrexone was administered orally and buprenorphine sublingually, so 
achieving the correct dose combination to achieve an antidepressant effect may not 
be trivial (Almatroudi et al., 2015, Cordery et al., 2014). Furthermore, the risk of 
diversion of buprenorphine and its abuse liability as a partial -opioid receptor 
agonist must be considered. The non-therapeutic mis-use of buprenorphine has 
recently been reported to be rising among drug users, as it serves as a substitute for 
other drugs of abuse (Cicero et al., 2014).   
 
An alternative strategy to targeting -receptors, building on this combination 
approach, is to design novel chemical entities that combine the pharmacology of 
buprenorphine and naltrexone into one molecule. This would overcome both the 
abuse liability issue and the dosing issues. BU10119 is one of a novel series of 
orvinol analogues in which the C20-methyl group has been moved to the C7-b 
position (Cueva et al., 2015, Figure 1). In vitro pharmacology studies have 
established that BU10119 has high affinity for both  and  receptors with little 
efficacy at either of these receptors indicating an antagonist like profile (Cueva et al., 
2015, Table 1). Here we report the initial characterization of BU10119 in vivo and 
behavioural studies that demonstrate the therapeutic antidepressant-like potential in 
mice. 
506/500 words  
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Table 1  
 
Maximal Stimulation of [35S]GTPS binding of buprenorphine and BU10119 to 
opioid and NOP receptors 
 
Compound   NOP 
Buprenorphine 
(1a*) 
0 ± 6%  
(Ke = 0.14 ± 0.06 
nM) 
20 ± 6%  
(EC50: 0.7 ± 
0.3nM) 
39 ± 12% 
(EC50: 1480 ± 980nM) 
BU10119 
(15a*) 
−2 ± 1%  
(Ke = 0.09 ± 0.04 
nM) 
2 ± 4%  
(Ke = 0.28 ± 0.04 
nM) 
56 ± 1% 
(EC50: 147 ± 33nM) 
 
Percent maximal stimulation at a single high concentration (10 M) with respect to the standard 
agonists U69,593 (), DAMGO () and nociception (NOP). Agonist EC50 (nM) or antagonist Ke (nM) 
the antagonist dissociation constant determined against the same agonists. Neither buprenorphine 
nor BU10119 has any appreciable efficacy at -receptors. All data taken from Cueva et al. 2015. 
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Methods  
Drugs 
BU10119 was synthesised and supplied at the University of Bath (Cueva et al., 
2015). Buprenorphine hydrochloride and morphine sulphate were purchased from 
MacFarlan Smith (Edinburgh, UK). U50,488 was obtained from Sigma (Dorset, UK). 
Clocinnamox mesylate (CCAM) and norBNI dihydrochloride were supplied by Tocris 
Bioscience (Bristol, UK). Fluoxetine hydrochloride and naltrexone hydrochloride were 
purchased from Abcam Biochemicals (Cambridge, UK). All drugs were injected via 
the intraperitoneal route at a volume of 10 ml/kg, except CCAM administered at 
20ml/kg, and were dissolved in 0.9% w/v saline (Hameln Pharmaceuticals, 
Gloucester, UK).  
 
Animals 
Adult male CD-1 mice weighing 25 to 43 g (8–10 weeks) were used throughout 
these experiments. CD-1 mice were initially from Charles River (Crl:CD1(ICR)) and 
bred in-house at the University of Bath for more than 10 years. At weaning, mice 
were housed as mixed litter groups of 4 to 5 in cages (30 x 16 x 14 cm) with wood 
shavings and nesting material and with ad libitum access to food and water. Mice 
were maintained on a 12 h light-dark cycle (lights on 07:00 hours, lights off 19:00 
hours) at 20 ± 2°C. All experiments were performed in accordance with the UK 
Home Office guidelines, including local ethical review, and the Animals (Scientific 
Procedures) Act 1986/ Directive 2010/63/EU. Mice were randomly assigned to 
treatment groups. All behavioural experiments were performed between 09:00 and 
16:00 hours by a male experimenter (Sorge et al., 2014) and mice were habituated 
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to the behavioural room for 1 h before starting an experiment. For each behavioural 
task separate groups of animals were used (n=5-18 per treatment group).  
 
Warm water tail-withdrawal test 
 
The warm water tail-withdrawal assay was carried out as described previously 
(Almatroudi et al., 2015). Water temperature was maintained at 52°C and the latency 
for tail withdrawal recorded. A 15-second cut-off was imposed to avoid tissue 
damage and antinociception calculated as percentage maximum possible effect 
(%MPE) = (test latency–control latency)/(15 s–control latency) ×100. To counteract 
any possible confounding effects of injection induced stress, in all experiments, 
animals received 0.9% w/v saline injections so that the total number of injections an 
individual mouse received, whether in control or in drug treated groups, was 
equivalent. 
 
To examine the duration of the -antagonist properties of BU10119 (0.3,1 and 3 
mg/kg), tail withdrawal latencies were determined at intervals 1-48 h post-injection, 
with antinociceptive agonist challenge (U50,488) administered 30  min prior to each 
time point (Figure 2B). The -antagonist properties of BU10119 (0.3, 1 and 3 mg/kg) 
were established by blockade of the -agonist induced antinociceptive effects of 
buprenorphine (1 mg/kg) and morphine (10 mg/kg), and compared to the irreversible, 
selective μ-antagonist CCAM (3 mg/kg) (Broadbear et al., 2000) (Figure 2C). 
Baseline latencies were measured immediately before injecting BU10119 or saline at 
time zero. Buprenorphine or morphine were injected 30 min later and 1 h elapsed 
before “test” tail-withdrawal latencies were measured. CCAM was injected 24 h 
before time zero (Broadbear et al., 2000) 
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To assess stress-induced analgesia, baseline latencies were measured before drug 
injection on the first and third day of restraint. These baseline latencies did not 
change across the duration of the experiment (Supplementary figure 1). BU10119 (1 
mg/kg) or buprenorphine/naltrexone (1 mg/kg) combination was given daily 1h 
before restraint (naltrexone (1 mg/kg) was injected 10 minutes prior to 
buprenorphine). Tail-withdrawal latency was measured 5 minutes after the end of the 
restraint session on the first and third day. For mice treated with norBNI (10 mg/kg), 
the drug was given once only 24 h before the first restraint session. 
 
Locomotor activity 
To investigate any potential sedative effect of BU10119 (0.3, 1 mg, and 3 mg/kg), 
locomotor activity was assessed 1 h post-administration in a 10 min open-field test 
(72 x 72 cm) under low light conditions (30 lux) via infrared photobeams (Almatroudi 
et al., 2015). 
 
Forced swim test 
Antidepressant-like effects of BU10119 (1 mg/kg), buprenorphine/naltrexone 
combination (1 mg/kg) and the selective serotonin reuptake inhibitor fluoxetine were 
investigated in a 6 min forced swim test (Almatroudi et al., 2015). All drugs were 
administered 1 h prior to testing and the behaviour during the last 4 minutes of the 
test reported. 
 
Novelty-induced hypophagia 
 
The novelty-induced hypophagia paradigm used was as previously described 
(Almatroudi et al., 2015). Mice were trained on 3 consecutive days to consume 
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condensed milk. The latency to drink milk was recorded on day 4 in the home cage 
and on day 5 in a novel cage environment. Mice received fluoxetine (20 mg/kg), 
BU10119 (1 mg/kg) and buprenorphine/naltrexone combination (1 mg/kg) 
(naltrexone was injected 10 minutes prior to buprenorphine) 1 h prior to testing. For 
mice receiving the -receptor antagonist norBNI (10mg/kg), the drug was injected 
immediately after training on day 3, 24-48 h prior to testing.  
 
Elevated plus maze (EPM) 
The time spent in, and entries into, the open and closed arms, and total ambulation 
during a 5 min EPM test were recorded via infrared photobeams (Almatroudi et al., 
2015). Illumination was 150 lux in the open arms and <1 lux in the closed arms. Mice 
were treated with saline, BU10119 (1 mg/kg), buprenorphine/naltrexone (1mg/kg) 
combination and diazepam (2mg /kg) 60 min prior to testing. 
 
Light Dark Box (LDB) 
The number of entries into and time spent in the lit compartment (400 lux), and the 
distance travelled during a 10 min LDB test were recorded via beam-breaks 
(Almatroudi et al., 2015). Mice were treated with saline, BU10119 (1 mg/kg), 
buprenorphine/naltrexone (1 mg/kg) combination and diazepam (2 mg /kg) 60 min 
prior to testing. 
 
Conditioned place preference (CPP) 
Place preference conditioning was conducted in a CPP chamber with an auto 
monitoring tracking system (Ethovision XT version 8.0, Tracksys, Nottingham, UK) 
as described previously (Almatroudi et al., 2015). Experiments were performed 
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between 09:00 hours and 16:00 hours under dim light (approximately 15 lux). During 
all test sessions, the time each mouse spent in each compartment was recorded. 
Mice were randomly assigned to treatment groups and the pairing was 
counterbalanced (i.e. within each treatment group equal numbers of mice were drug-
paired to each compartment type). On days 1 and 2 mice were habituated to the 
entire chamber for 15 minutes (one session/day), during which baseline preference 
scores were taken. On days 3–8 mice were conditioned (40 minutes) to one of the 
two compartments, and daily sessions alternated between drug treatment and saline 
(In all treatment groups mice received both drug and saline). Mice were given 
buprenorphine (1 mg/kg), BU10119 (1mg/kg), morphine (10 mg/kg) or saline (0.9 % 
w/v). Where CCAM (3 mg/kg) was injected this was 24 hr before conditioning and 
mice were immediately returned to the home cage. After buprenorphine injection, the 
mice were transferred directly to the place preference  box  and  at  the  end  mice  
were  returned  to  their home cage. Chamber floors and trays were removed and 
cleaned with ethanol 70% and left for 5 minutes for ethanol to evaporate before the 
next trial. On day 9, mice were not injected with saline or drugs. In a free-to-explore 
test, lasting 15 minutes, mice had free access to both compartments and their 
preference was determined by recording the time spent in the drug-paired chamber. 
Data are presented as preference for drug-paired side of CPP chamber, determined 
as the time spent in drug paired side minus time spent in drug paired side pre-
conditioning (baseline). 
 
Restraint stress  
Mice in restraint-stressed groups were restrained in a well-ventilated modified 50 ml 
syringe for 2 h on 3 consecutive days from 09:00-11:00 hours (Sadler and Bailey, 
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2016). Stressed mice were weighed daily, monitored and scored for signs of stress. 
Non-stressed control mice were weighed daily and returned to their home cage.  
 
Measurement of corticosterone level 
All blood samples were collected from the lateral tail vein using the tail nick method 
and the minimal blood volume (~40 l) collected in a heparinised capillary tube 
(Sadler and Bailey, 2013). Samples were taken at baseline, 24 h before the first 
restraint session, and immediately following the end of restraint stress (11:00 to 
13:00 hours). Blood was collected in centrifuge tubes containing EDTA (final 
concentration in sample 3 g/l) and kept on ice until being centrifuged for 20 min at 
4°C at 2000rcf. Plasma was taken and stored at -20°C until analysed using an ELISA 
kit (IBL International, Hamburg, Germany) to determine the level of corticosterone. 
 
 
Statistical analysis 
 
All data were analyzed using two-way repeated measures mixed model analysis or 
single measures one-way analysis of variance (ANOVA) followed by Unadjusted 
Least Significant Difference (ULSD) post hoc test (InVivoStat 2.3). Only planned 
pairwise tests were carried out and p values adjusted for multiple comparisons with 
Benjamin-Hochberg correction. In CCAM, buprenorphine and morphine CPP study 
unpaired Student’s t-test was used. Values are reported as mean ± standard error of 
the mean (SEM) for each treatment group. 
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Results   
 
Establishing the opioid receptor pharmacology of BU10119 in vivo 
Pilot studies in mice revealed no overt signs of toxic effects of BU10119 at doses up 
to 10 mg/kg using a minimal numbers approach (n=3 per dose) (Hillhouse et al. 
2016). The in vivo pharmacology of BU10119 was established using the warm water 
tail withdrawal test in adult male CD1 mice. BU10119 at 0.3, 1 and 3 mg/kg 
produced no significant antinociceptive action up to 4 h post-injection (Figure 2A; 
n=5 per group).  Two-way repeated measures mixed model analysis revealed a 
significant interaction of Treatment*Time (F(12,60) = 19.35, p< 0.001). Post-hoc 
testing showed that only buprenorphine (1mg/kg) produced a significant 
antinociceptive effect compared to saline treated controls, that peaked at 60 min 
post-administration (p<0.001) and returned to baseline after 240 min.  
 
To determine the -antagonist properties of BU10119 (0.3, 1 and 3mg/kg), its ability 
to block U50,488-induced antinociception was determined at 1, 8, 24 and 48 hours 
post-administration (Figure 2B; n=5 per group). Two-way repeated measures mixed 
model analysis revealed that there was a significant interaction of Treatment*Time 
(F(28,140)= 5.46, p<0.001). U50,488 produced a pronounced antinociceptive effect 
that was significantly reduced by BU10119 (1 and 3 mg/kg) at 1, 8 and 24 h post-
administration (p <0.001) but not at 48h. The high affinity, selective -antagonist 
norBNI (1 mg/kg) was able to block U50,488-induced antinociception at all-time 
intervals tested (all p’s <0.001, compared to U50,488).  
 
In addition to-antagonist properties, BU10119 demonstrated -antagonist 
properties in the tail withdrawal assay (Figure 2C). Two-way repeated measures 
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mixed model analysis revealed that there was a significant interaction of 
Treatment*Time (F(7,28) = 18.68, p<0.001). Post-hoc testing showed that BU10119 (≥ 
1mg/kg) significantly blocked the antinociceptive effect of buprenorphine (1mg/kg) 
(p<0.001) and morphine (10mg/kg) (p<0.001) 60 min post-administration. The 
irreversible μ-antagonist CCAM (3 mg/kg), administered 24h before buprenorphine 
or morphine, was also able to block antinociception significantly (p’s<.0.001). Taken 
together these data show that, in vivo, BU10119 is a mixed /-antagonist with 
relatively short acting -antagonist activity (24-48 h). 
 
Effects of BU10119 on locomotor activity 
The open-field arena was used to assess the locomotor effects of BU10119 (0.3, 1 
and 3 mg/kg) in CD-1 male mice. There were no significant effects of BU10119 on 
locomotion (F (3,16)= 1.65, p=0.218) (Figure 3). However, there was an apparent 
trend for increased locomotion at 3mg/kg. For this reason, in subsequent behavioural 
tasks, BU10119 was investigated at 1mg/kg alone.  
 
Effects of BU10119 in the conditioned place preference (CPP) task 
One-way ANOVA revealed a significant effect of Treatment on the preference for the 
drug paired compartment of the CPP chamber (F (5,48)= 6.78, p<0.0001). Mice 
receiving 1mg/kg of buprenorphine exhibited significant conditioned place preference 
compared to saline treated mice (p <0.01, n= 9 per treatment group, Figure 4A). 
BU10119 at the same dose appeared to increase preference for the drug-paired side 
although this effect was not significant (p= 0.08). The irreversible -antagonist 
CCAM (3mg/kg), was administered 24 h before saline, buprenorphine or BU10119. 
Interestingly, CCAM appeared to reduce the effects of BU10119 in the CPP chamber 
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(p=0.058). However, CCAM failed to block or to reduce the effects of buprenorphine 
in the CPP chamber (p=0.914). CCAM alone was neither rewarding nor aversive. 
There were no significant differences in baseline times, determined pre-conditioning, 
between any of the treatment groups. 
  
 
In a subsequent experiment (Figure 4B), CCAM (3mg/kg) was able to significantly 
block the rewarding effects of morphine in the CPP task. One way ANOVA revealed 
that there was a significant effect of treatment on the preference for the drug paired 
side (p<0.05). However, CCAM (3mg/kg) was again not able significantly to reduce 
the time spent in the drug paired side for buprenorphine (1mg/kg) (p = 0.3838, n = 8 
per treatment group, unpaired t-test). Taken together these data show that in 
contrast to the tail withdrawal assay, BU10119 may have some weak -agonist 
activity in the CPP task. The apparent increase in preference for the drug paired side 
shown by BU10119, although not significant, may suggest weak -agonist properties 
that are blocked by the irreversible antagonist CCAM. Interestingly, 
buprenorphine’s rewarding effects in the CPP task are not apparently mediated via 
its partial -agonist activity. 
 
Effects of BU10119 on depression- and anxiety related behaviours 
The antidepressant-like effects of BU10119 were assessed using the forced swim 
test (FST) and the novelty-induced hypophagia task. One-way ANOVA revealed a 
significant effect of Treatment on the time spent swimming (F(3, 36)=6.58, p<0.001) 
and immobile (F(3, 36)=7.02, p<0.001) during the last 4 minutes of a forced swim test 
session (Figure 5A) . Post hoc analysis revealed that BU10119 (1mg/kg), 
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combination buprenorphine/naltrexone (1 mg/kg) and fluoxetine (20 mg/kg) 
increased the time spent swimming and decreased the time spent immobile 
compared to saline treated controls (n=10 per treatment group, all p’s <0.001). 
 
In the novelty-induced hypophagia task (Figure 5B), two-way repeated measures 
mixed model analysis of the latency to drink times revealed significant main effects 
of Treatment (F(4,75)=6.13, p<0.001) and a significant Treatment*Environment 
interaction (F(4,75)=5.92, p<0.001).  The novel cage was shown to be aversive as 
saline control treated mice showed a significant increased latency to drink milk in the 
novel cage (latency= 7.32± 0.94 min) versus the home cage (latency= 0.48± 0.10 
min, p<0.001). Within treatment, post-hoc comparisons to saline treated controls 
revealed that all drug treated groups decreased the latency to drink milk in the novel 
cage (n=10 per treatment group, all p’s <0.001).   
 
In the EPM, one-way ANOVA, showed significant effects of Treatment on the time 
spent in (F(3, 36)=3.29, p< 0.05) and number of entries into (F(3, 36)=3.89, p<0.01) the 
open arms (Figure 6 (A–C), n=10 per group). Post hoc comparisons to saline treated 
controls revealed that only the benzodiazepine diazepam (2 mg/kg) significantly 
increased these parameters (p<0.01). Interestingly, both buprenorphine/naltrexone 
(1 mg/kg) combination and BU10119 (1 mg/kg) did not show any significant changes 
in behaviours in the EPM. Total ambulation in the EPM was not affected by drug 
treatment (F(3,36)=1.15 p=0.342), showing an absence of any sedative effects. 
Furthermore, in the LDB there were no significant effects of either BU10119 or 
combination buprenorphine/naltrexone (Figure 6(D–F), n=18 per group). One-way 
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ANOVA revealed a significant main effect of Treatment on the time spent in the light 
(F(3, 60)=3.59, p< 0.01) and dark (F(3 ,60)=3.59, p< 0.01) compartment of the LDB. 
However, within-treatment analysis to saline controls showed that only diazepam (2 
mg/kg) significantly increased the total time spent in the lit compartment (p<0.01). As 
with the EPM, total ambulation in the LDB was not significantly affected by drug 
treatment (F(3,60)= 1.26, p= 0.29). 
 
 
Stress induced analgesia and elevation in corticosterone level 
To assess whether BU10119 or combination buprenorphine/naltrexone could block 
the effects of stress in adult male mice, stress-induced analgesia was assessed in 
the warm water tail-withdrawal assay (Figure 7A). Two-way repeated measures 
mixed model analysis revealed a significant interaction of Treatment*Time (F(12,75) = 
23.3, p< 0.001). Exposure to acute restraint (1 x 2h restraint) or 3 days repeated 
restraint stress (3 x 2h restraint) produced a significant stress-induced analgesia 
evident as an antinociceptive effect in restraint stressed mice compared to non-
stressed controls (p<0.001, n= 6 per treatment group). Pre-treatment with BU10119 
(1mg/kg), combination buprenorphine/naltrexone (1mg/kg) or the selective -
antagonist norBNI (10mg/kg) blocked stress-induced analgesia (p< 0.001), 
compared to respective acute or repeated stressed saline control groups. 
Furthermore, there was no significant difference between the baseline tail withdrawal 
latency in non-stressed control groups in the first and third day of experiment (p= 
0.3344).   
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Blood samples were collected at baseline (24 h pre-stress) and after 3 days 
repeated restraint stress, from the same animals, for analysis of corticosterone levels 
(Figure 7B). Two-way repeated measures mixed model analysis revealed that there 
was a significant effect of stress (F(1,21)=62.62, p<0.001), no significant effects of 
treatment  (F(4,25)=1.2, p<0.3299) but a significant interaction Stress * Treatment 
(F(4,21)=13.14, p<0.001) on plasma corticosterone levels. Post-hoc comparisons 
revealed no significant difference in baseline plasma corticosterone levels in all mice 
prior to treatment. However, following 3 days of repeated restraint stress, there was 
a significant effect of stress in all drug-treated groups compared to non-stressed 
saline-injected controls (all p≤0.01) but none of the drug treatments were able to 
block stress-induced increases in plasma corticosterone (all ps >0.05). 
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Discussion 
 
We have previously shown that the combined administration of buprenorphine and 
naltrexone produces antidepressant-like effects in mice (Almatroudi et al., 2015). 
BU10119 is a recently reported novel compound with an in vitro pharmacology that 
resembles the combination of buprenorphine/naltrexone: high affinity/ zero efficacy 
at -opioid receptors, high affinity/ little efficacy at -opioid receptors and a weak 
partial agonist profile at NOP receptors (Cueva et al., 2015). Here we report for the 
first time the in vivo pharmacology of BU10119 in adult male CD1 mice. The data 
shows BU10119 has a mixed -antagonist profile and the -antagonist effects are 
relatively short-acting with no activity evident at 24-48 h post-administration. We also 
show for the first time the antidepressant-like properties of BU10119 in the forced 
swim test and the novelty-induced hypophagia task. Importantly, BU10119 is without 
significant locomotor effects at the doses used and has no significant rewarding 
effects in the conditioned placed preference task.  Finally, we have shown that 
BU10119 is able to block stress-induced analgesia, although it did not reduce stress-
induced increases in plasma corticosterone. 
 
In the tail withdrawal assay, BU10119 (0.3 to 3 mg/kg) was without significant 
analgesic effects suggesting it has no agonist efficacy at any of the opioid receptors 
at the doses studied. Furthermore, BU10119 (1mg/kg and 3 mg/kg) was able to 
significantly reduce the analgesic effects of the -agonist U50,488 and of the -
agonists buprenorphine and morphine. These data clearly indicate that BU10119 has 
a mixed -antagonist profile in vivo. These results are consistent with in vitro 
studies using the rodent vas deferens which found that BU10119 acts as a -opioid 
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receptor antagonist, with an average pA2 value of 9.831 (9.084-10.58), and a 
competitive reversible antagonist at µ-opioid receptors with a pA2 value of 10.08 
(9.847-10.310) (Ridzwan, 2012). We have previously shown that naltrindole-derived 
compounds with a similar mixed -antagonist profile may have antidepressant and 
anxiolytic potential (Casal-Dominguez et al., 2013). However, those compounds had 
long lasting -antagonist effects; 21-35 days following a single injection (Casal-
Dominguez et al., 2013). Experiments in the tail-withdrawal assay show the time 
course of BU10119’s -antagonist effects. Interestingly, BU10119’s effects in the tail 
withdrawal assay are not evident 24-48h post-administration making it a relatively 
short-acting -antagonist. This is slightly longer than the duration of action of 
combination buprenorphine/naltrexone or naltrexone alone which have a duration of 
effect <24h (Almatroudi et al. 2015) but shorter than the prototypical -antagonist 
norBNI (Casal-Dominguez et al., 2013).   
 
While BU10119 (1mg/kg) was without any agonist efficacy in the tail-withdrawal 
assay, or in in vitro GTPS assays (Table 1), the conditioned place preference task 
revealed that BU10119 may be a weak partial -agonist. Measures of partial agonist 
activity in GTPS assays are dependent on specific experimental design such as 
expression levels. Indeed, naltrexone has been reported to have partial -agonist 
activity under conditions of high receptor expression (Kelly et al., 2015). BU10119 
appeared to increase the time spent in the drug-paired compartment of the CPP 
apparatus, although not to the same extent as buprenorphine, and this effect was not 
statistically significant. Interestingly, the irreversible -antagonist CCAM (3mg/kg) 
was able to reduce the apparent rewarding effects of BU10119 suggesting that these 
effects are mediated by BU10119 activating -opioid receptors. We confirmed that 
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CCAM was acting to block -opioid receptors as it reduced the ability of morphine to 
produce conditioned place preference in a separate experiment. Interestingly, in both 
CPP experiments performed here the rewarding properties of buprenorphine were 
not reversed by CCAM. This is consistent with findings in -receptor knockout mice 
that buprenorphine maintains its rewarding properties (Ide et al., 2004). However, in 
another study using different CPP protocols and different-opioid receptor knockout 
mice, conditioned place preference to buprenorphine was not demonstrated 
(Marquez et al., 2007). Ide et al.  (2004) also showed that the nonselective opioid 
antagonist naloxone, and to a lesser extent the -antagonist naltrindole, and the -
antagonist norBNI were able to reduce buprenorphine conditioning suggesting that 
multiple opioid receptors are involved in mediating the rewarding effects of 
buprenorphine. It is interesting that the antidepressant drug fluoxetine has also been 
shown to produce conditioned place preference (Collu et al., 1997), suggesting that 
perhaps any drug with a positive, stress-relieving action may somewhat increase 
preference for the drug paired compartment. 
 
BU10119 shows antidepressant-like activity in both the forced swim test and the 
novelty-induced hypophagia test. The acute administration of the SSRI fluoxetine 
has been shown previously to reduce the time spent immobile in the mouse forced 
swim test; a widely used behavioural screen for antidepressant efficacy (Lucki, 1997, 
Cryan et al., 2002). Our data show that BU10119 produces effects equivalent to 
fluoxetine in the forced swim test. We have previously reported the effects of norBNI (10 
mg/kg) in adult male CD-1 mice in the forced swim test 6, 13 and 20 days post-
administration (Casal Dominguez et al., 2013) and 24-48 h post administration (Almatroudi 
et al., 2015). In both these experiments, norBNI produced responses equivalent to 
Antidepressant-like effects of BU10119 
 
22 
 
fluoxetine.  The novelty-induced hypophagia task is a procedure developed to assess 
anxiety-related behaviours using a conflict based approach-avoidance task that is 
sensitive to a range of anxiety-relieving drugs including chronic, but not subchronic, 
administration of fluoxetine (Dulawa and Hen, 2005). Here we have shown that acute 
fluoxetine (20 mg/kg) delivered by intraperitoneal injection, 1 h prior to testing in both 
the home and novel cage, did reduce the latency to feed in the novel cage in CD-1 
mice, as we have previously reported (Almatroudi et al. 2015). Several procedural 
variations could account for these observations including mouse strain and route of 
administration: Dulawa and Hen (2005) examined a range of doses of fluoxetine (0-
25 mg/kg) delivered via drinking water to BALB/cJ mice for 4-5 days (subchronic) or 
for 28/29 days (chronic). Furthermore, Dulawa and Hen administered fluoxetine 
throughout the training period whereas fluoxetine was only administered here during 
the testing period. The behavioural effects of BU10119 in both the forced swim test 
and novelty-induced hypophagia tasks resembled that of the SSRI fluoxetine and the 
combination of buprenorphine/naltrexone suggesting that it has antidepressant-like 
activity.  
 
Interestingly, BU10119 was without any appreciable effects in the elevated plus 
maze and light dark box tasks. This is similar to our previous studies with 
combination buprenorphine/naltrexone and naltrexone alone (Almatroudi et al., 
2015). This is perhaps surprising given that dynorphin has been shown to induce 
significant anxiogenic like effects in mice in the elevated plus maze (Narita et al., 
2005) while high affinity selective -antagonists, norBNI and JDTic, have been 
shown to produce anxiolytic like effects (Knoll et al., 2007). A lack of anxiolytic-like 
effect in the elevated plus maze may be related to the duration of -antagonist 
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effects. We have previously shown that long-acting mixed -antagonists, and the 
selective antagonist nor-BNI, have anxiolytic-like activity in these tasks when 
tested 7 and 14 days post-administration (Casal-Dominguez et al. 2013). BU10119, 
naltrexone and combination buprenorphine/naltrexone are relatively short-acting -
antagonists and don’t display this anxiolytic-like effect in the elevated plus maze and 
light dark box (Almatroudi et al., 2015). Similar findings have been reported with the 
short-acting -antagonists zyklophin and LY2444296 which have effects in a novelty-
induced hypophagia paradigm but no anxiolytic-like activity in the elevated plus 
maze (Huang et al., 2016). This was in contrast to norBNI which they showed to be 
effective in both behavioural paradigms, as we have shown previously, also in CD1 
mice (Casal Dominguez et al., 2013; Almatroudi et al. 2015). The duration of activity 
of -receptor antagonists has been demonstrated to correlate with c-Jun N-terminal 
kinase-1 activation (Melief et al. 2011). It is not clear whether long duration of -
antagonist action is required to produce behavioural effects in the elevated plus 
maze as other short-acting -antagonists, AZ-MTAB, and LY-DMPF, have been 
shown in prenatally stressed rats to exhibit anxiolytic type responses (Peters et al., 
2011). The absence of a robust anxiolytic like effect of BU10119 in naïve mice may 
be due to the fact that the elevated plus maze and light dark box are not sufficiently 
stressful paradigms to activate dynorphin release and alter anxiety behaviours 
(McLaughlin et al., 2006a, Shirayama et al., 2004, Wittmann et al., 2009). 
 
The phenomenon of stress-induced analgesia is an endogenous protective 
mechanism that occurs in response to stressful stimuli and involves activation of the 
descending inhibitory pain pathways (Butler and Finn, 2009). In this study we have 
used the warm-water tail withdrawal assay to assess stress-induced analgesia. This 
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model may be complicated by stress-induced changes in skin temperature arising 
from vasoconstriction, but this does not preclude an interpretation of stress-induced 
analgesia (Butler and Finn, 2009). Acute stress has been shown to produce 
antinociception whereas prolonged or repeated exposure to the stress results in 
tolerance or even hyperalgesic responses (Seo et al., 2011, Seo et al., 2006, 
Gamaro et al., 1998). Different types of stressors including restraint, cold-swim or 
presence of a predator can elicit opioid mediated stress-induced analgesia, which 
activates distinct neuroanatomical structures (Keay and Bandler, 2001). In this study, 
we show that both acute and repeated restraint stress resulted in stress-induced 
analgesia that was blocked by pre-treatment with BU10119 and the combination 
buprenorphine/naltrexone. Restraint stress-induced analgesia is blocked by pre-
treatment with the -antagonist norBNI in female rats (Botelho et al., 2010) and in 
mice exposed to forced swim stress (McLaughlin et al., 2003). Interestingly, forced 
swim stress-induced analgesia has been shown to be absent in prodynorphin -/- 
mice (McLaughlin et al., 2003) but is not altered in -receptor knockout mice (Contet 
et al., 2005). As these authors discuss,-receptor and prodynorphin knockouts are 
not equivalent animal models since the prodynorphin gene encodes a number of 
opioid peptides that activate opioid receptors (Contet et al., 2005). There are also 
differences in these studies in the application of the forced swim stress and in the 
methodology to assess stress-induced analgesia.  Here, we have demonstrated that 
restraint stress-induced analgesia is blocked by -antagonists suggesting the 
possibility that these compounds may have a role as prophylactic stress treatments 
(Van’t Veer and Carlezon, 2013). 
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Interestingly, BU10119 was not able to block stress-induced increases in plasma 
corticosterone. There are contradictory reports in the literature about the impact of -
receptors on plasma corticosterone levels. McLaughlin et al. (2006) used repeated 
forced swim stress in C57BL/6 mice which produced a 3-fold increase in plasma 
corticosterone. They went on to show that following pretreatment with the -
antagonist norBNI, and in prodynorphin knockout mice, swim stress still produced an 
increase in plasma corticosterone. However, Wittmann et al. (2009) reported that 
basal corticosterone serum levels were reduced in prodynorphin knockout animals 
and in wildtype mice pretreated with 10 mg/kg norBNI. In food restricted rats 
elevated plasma corticosterone levels were reduced by treatment with norBNI (Allen 
et al., 2013). However, swim stress in rats induced elevated plasma corticosterone 
that was not blocked by norBNI treatment (Polter et al., 2014). Contet et al. (2005) 
used a swim stress in warm water in-receptor knockout mice and suggested the 
dissociation of stress-induced analgesia and stress-induced increases in plasma 
corticosterone levels. These apparently contradictory findings could be explained in 
part by the different stressors used which would likely implicate different circuitry in 
the stress coping behaviours (Pacák and Palkovits, 2001). It is noteworthy that in all 
of these studies, stress-induced behaviours were blocked by treatment with norBNI, 
or in dynorphin -/- mice, even though stress-induced corticosterone levels may or 
may not have been affected. Thus -antagonists may have therapeutic potential in 
treating stress-induced behaviours independent of effects on corticosterone levels 
(Carroll and Carlezon, 2013, Van’t Veer and Carlezon, 2013).   
 
Naltrexone is a relatively non-selective opioid receptor antagonist with higher affinity 
for  than -opioid receptors. In the UK it is licensed as an abstinence promoter 
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(Rosner et al., 2010). However, naltrexone is associated with aversive side effects. 
Combining naltrexone (50 mg daily) with buprenorphine (4 mg daily) has been 
shown to improve patient compliance in the treatment of opioid dependence, as this 
improves the dysphoria associated with drug withdrawal (Gerra et al. 2006). 
However, the tolerability of naltrexone has been shown to be significantly improved 
when given at lower doses and low dose naltrexone (< 4mg daily) is increasingly 
being used for the treatment of a number of chronic conditions (Segal et al., 2014, 
Younger et al., 2014).  Low dose naltrexone has recently been trialled in a small 
cohort of major depressive disorder patients, maintained on antidepressant therapy 
but experiencing a relapse (Mischoulon et al., 2017). This study investigated whether 
augmentation of dopaminergic antidepressant regimens (mostly buproprion) with 
1mg naltrexone for 3 weeks would reduce Hamilton Depression Scale (HAM-D17) 
scores by 50% compared to baseline. There was an apparent effect of low dose 
naltrexone although it was not significantly different from placebo in this small cohort 
study (Mischoulon et al., 2017). The potential of opioid antagonist mechanisms for 
the treatment of depression is also evident in the combination of buprenorphine with 
the -antagonist samidorphan producing a functional mixed /-antagonist (Ehrich et 
al., 2015). Following 7 days of once daily buprenorphine/samidorphan at a 1:1 ratio, 
patients with treatment resistant major depressive disorder showed a significant 
improvement in HAM-D17 total score (Ehrich et al., 2015). These clinical findings, 
coupled with our preclinical data, suggest that molecules like BU10119 with a 
pharmacology resembling combination buprenorphine/naltrexone could have 
significant potential in the treatment of depression.  
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Figures 
 
Figure 1 Chemical structures of buprenorphine and BU10119. 
 
Figure 2 Effects of BU10119 in adult male CD1 mice in the warm water tail 
withdrawal assay. The time course of the experiments is indicated and tail 
withdrawal latencies are expressed as % maximum possible effect (%MPE). (A) 
Antinociceptive effects of buprenorphine (1 mg/kg) and BU10119 (0.3, 1 and 3 
mg/kg). ***p< 0.001 as compared between buprenorphine and all other groups. (B) 
Antinociceptive effects of the -agonist U50,488 (10 mg/kg) were blocked by 
BU10119 (1 and 3 mg/kg) and by norBNI (1 mg/kg). ***p< 0.001 as compared to 
BU10119 (1 and 3 mg/kg) and norBNI (1mg/kg), ###p<0.001 as compared between 
all groups and norBNI (1mg/kg). (C) Antinociceptive effects of buprenorphine and 
morphine at 60 min post-administration were blocked by BU10119 (1 mg/kg) and by 
the irreversible μ-antagonist CCAM (3 mg/kg). ***p< 0.001 compared to 
buprenorphine, ###p< 0.001 compared to morphine.  All values are mean ± SEM, n= 
5 per group, separate experimental groups in each figure.  
 
Figure 3 Locomotor activity in the open field in adult male CD1 mice treated with 
BU10199 (0.3, 1 and 3mg/kg). All values are mean ± SEM, n=5 per group. No 
statistically significant effects on locomotion were observed. 
 
Figure 4 Conditioned place preference to buprenorphine (BUP, 1mg/kg), BU10119 
(1mg/kg) and morphine (10 mg/kg). Two separate experiments were conducted. (A) 
BU10119 did not produce significant conditioned place preference. Conditioned 
place preference to buprenorphine was not blocked in the presence of the 
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irreversible -antagonist CCAM (3mg/kg). (B) The activity of CCAM as a -
antagonist was confirmed by its ability to block morphine-induced conditioned place 
preference. Data are presented as preference for drug-paired side of CPP chamber, 
determined as the time spent in drug paired side (post-conditioning) minus time 
spent in drug paired side pre-conditioning (baseline). All data points are mean ± 
SEM. (A) **p< 0.01 compared to saline, n=9 per treatment group. (B) *p< 0.05 
compared to morphine, n=8 per treatment group. 
 
Figure 5 Effects of BU10119 (1mg/kg) in adult male CD1 mice in the forced swim 
test (A) and in the novelty-induced hypophagia task (B). The SSRI fluoxetine 
(20mg/kg) was administered as a positive control. The effects of combination of 
buprenorphine with naltrexone (both at 1mg/kg, BUP/NTX) and the -antagonist 
norBNI are also shown. (A) The total time spent swimming, climbing or immobile 
during the last 4 min of the forced swim session are shown. (B) The latency to drink 
milk in both the home and novel cage environments is shown. All values are the 
mean ± SEM (n=10 per group, separate experimental groups in each figure). ***p 
<0.001 as compared to saline,  ### p< 0.001 for comparison between groups. 
 
Figure 6 Effects of BU10119 (1mg/kg) in adult CD1 male mice in the elevated plus 
maze (A–C) and in the light-dark box (D–F). The effects of combination of 
buprenorphine with naltrexone (both at 1mg/kg, BUP/NTX) are also shown. The 
benzodiazepine diazepam (2 mg/kg) was used as a positive control. The time spent 
in the open arms (A), number of entries into the open arms (as a percentage of the 
total entries into open and closed arms) (B) and total ambulation (C) in the elevated 
plus maze are shown (n=10 per group). The time spent in the light box (D), in the 
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dark box (E) and total ambulation (F) in the light-dark box are shown (n=18 per 
treatment group, n=10 for BU10119). All values are the mean ± SEM. **p< 0.01 
compared to saline. 
 
Figure 7 Ability of BU10119 (1mg/kg), combination buprenorphine/naltrexone (both 
at 1mg/kg, BUP/NTX) and the -antagonist norBNI to block stress-induced effects. 
Drug treatments were administered 1h prior to acute restraint stress (1 x 2h, Day 1) 
and daily repeated restraint stress (3 x 2h, Day 3) in adult male CD1 mice. (A) 
Stress-induced analgesia was evident, in the warm-water tail withdrawal assay, as 
increased % maximum possible effect (%MPE). Test latencies were assessed 
immediately following the restraint session.  ***p< 0.001 compared to all groups 
within the same day. (B) Blood samples were taken at baseline and immediately 
following the last session of restraint to assess plasma corticosterone. All blood 
samples were taken during the light phase 11:00-13:00 h. ***p<0.001, compared to 
non-stress saline post day 3.  ## p<0.01,### p<0.001, compared to baseline for the 
same treated group. All values are the mean ± SEM (n=6 per group, separate 
experimental groups in A and B). 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5  
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Figure 6 
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Figure 7 
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Supplementary figure 1    
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Supplementary figure 1 (A) Effect of 1 day and 3 day restraint stress (09:00-11:00) 
on stress-induced analgesia in CD1 male mice. (B) Baseline latency on day 3. 
Results are expressed as mean ± SEM, n=4. ***p<0.001 as compared to non-
stressed controls. Analysis done was repeated measures mixed model analysis 
using InVivo Stat software.  
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